Intellia Therapeutics' Lonvo-z Nears Regulatory Approval in 2027
Intellia Therapeutics, a gene-editing biotech firm backed by Ark Invest and Cathie Wood, is on the verge of regulatory approval for its lead candidate lonvo-z. The therapy showed promising Phase 3 results with an 87% reduction in HAE attacks compared to placebo. Intellia plans to submit U.S. applications that could result in a March 2027 decision. Despite positive data, the company remains unprofitable and has no approved products yet. While approval is seen as a milestone, it may already be priced into shares given mixed market reactions after prior updates. Lonvo-z's potential revenue from HAE patients is estimated at $7 billion in the U.S., though adoption could take years. The company also faces challenges with its other candidate, nex-z for ATTR amyloidosis, which has had safety concerns and clinical holds despite recent progress.
Tickers: $NTLA
Topics: gene-editing hereditary angioedema (HAE) Phase 3 results regulatory approval